Your browser is no longer supported. Please, upgrade your browser.
PRTK Paratek Pharmaceuticals, Inc. daily Stock Chart
Paratek Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.00 Insider Own3.70% Shs Outstand43.63M Perf Week-3.13%
Market Cap232.40M Forward P/E- EPS next Y-0.89 Insider Trans-2.11% Shs Float41.32M Perf Month-11.29%
Income-110.70M PEG- EPS next Q-0.61 Inst Own50.70% Short Float9.16% Perf Quarter8.08%
Sales30.10M P/S7.72 EPS this Y-10.20% Inst Trans-0.18% Short Ratio6.13 Perf Half Y10.99%
Book/sh-1.45 P/B- EPS next Y53.90% ROA-45.90% Target Price- Perf Year43.48%
Cash/sh3.98 P/C1.24 EPS next 5Y- ROE222.50% 52W Range2.50 - 6.72 Perf YTD22.83%
Dividend- P/FCF- EPS past 5Y12.90% ROI-52.40% 52W High-26.34% Beta1.44
Dividend %- Quick Ratio6.00 Sales past 5Y30.70% Gross Margin78.70% 52W Low98.00% ATR0.34
Employees102 Current Ratio6.50 Sales Q/Q365.00% Oper. Margin- RSI (14)42.31 Volatility6.76% 5.58%
OptionableYes Debt/Eq- EPS Q/Q48.40% Profit Margin- Rel Volume0.35 Prev Close5.12
ShortableYes LT Debt/Eq- EarningsAug 10 BMO Payout- Avg Volume617.28K Price4.95
Recom1.40 SMA20-8.25% SMA50-4.87% SMA20011.12% Volume213,064 Change-3.32%
Jan-08-20Initiated WBB Securities Speculative Buy $6
Jan-02-19Initiated Canaccord Genuity Buy $14
Nov-23-18Reiterated H.C. Wainwright Buy $55 → $22
Aug-27-18Initiated BofA/Merrill Neutral $13
Mar-02-18Downgrade Raymond James Strong Buy → Outperform
Oct-24-17Initiated Guggenheim Buy $44
Jul-18-17Reiterated H.C. Wainwright Buy $36 → $43
May-19-17Initiated Raymond James Strong Buy
Apr-11-17Reiterated H.C. Wainwright Buy $33 → $36
Apr-04-17Reiterated Wedbush Outperform $30 → $34
Apr-04-17Initiated Wedbush Outperform $30
Oct-27-16Resumed Leerink Partners Outperform $23
Jun-17-16Reiterated H.C. Wainwright Buy $31 → $34
May-13-16Initiated Robert W. Baird Outperform $30
Mar-30-16Resumed Cantor Fitzgerald Buy $27
Feb-29-16Initiated H.C. Wainwright Buy $32
Jul-22-15Initiated Gabelli & Co Buy $34
May-15-15Initiated Leerink Partners Outperform
May-12-15Initiated Cantor Fitzgerald Buy $35
May-11-15Initiated Guggenheim Buy $38
Oct-21-20 08:00AM  
Sep-09-20 04:01PM  
Sep-01-20 04:05PM  
Aug-25-20 10:17AM  
Aug-10-20 08:45AM  
Aug-05-20 04:01PM  
Aug-03-20 04:05PM  
Jul-28-20 04:01PM  
Jul-05-20 03:05PM  
Jun-12-20 04:46PM  
May-29-20 08:30AM  
May-28-20 08:00AM  
May-11-20 04:05PM  
Apr-30-20 08:00AM  
Apr-28-20 12:14PM  
Apr-14-20 12:26PM  
Apr-02-20 08:00AM  
Apr-01-20 08:00AM  
Mar-14-20 10:55AM  
Mar-10-20 05:12PM  
Mar-02-20 04:05PM  
Feb-27-20 11:50AM  
Feb-26-20 08:00AM  
Feb-25-20 05:35PM  
Feb-24-20 07:00AM  
Feb-17-20 01:36PM  
Feb-13-20 04:01PM  
Jan-14-20 03:12PM  
Dec-20-19 08:38AM  
Dec-19-19 09:33PM  
Dec-18-19 05:12PM  
Dec-13-19 03:06PM  
Dec-10-19 12:22PM  
Dec-06-19 08:00AM  
Dec-02-19 04:05PM  
Nov-30-19 11:02AM  
Nov-28-19 06:59PM  
Nov-13-19 12:14PM  
Nov-12-19 05:15PM  
Nov-05-19 10:31AM  
Nov-04-19 04:05PM  
Nov-01-19 04:05PM  
Oct-31-19 04:05PM  
Oct-29-19 10:32AM  
Oct-18-19 07:07AM  
Oct-17-19 04:05PM  
Oct-01-19 04:30PM  
Sep-25-19 08:00AM  
Sep-24-19 08:50AM  
Sep-23-19 01:16PM  
Sep-10-19 01:58PM  
Sep-09-19 08:00AM  
Sep-04-19 08:00AM  
Sep-03-19 04:05PM  
Aug-30-19 01:31PM  
Aug-26-19 04:05PM  
Aug-13-19 02:07AM  
Aug-06-19 05:45PM  
Aug-01-19 04:05PM  
Jul-29-19 04:05PM  
Jul-25-19 10:33AM  
Jul-17-19 04:02PM  
Jul-10-19 07:00AM  
Jul-05-19 03:59PM  
Jul-01-19 09:13AM  
Jun-25-19 04:01PM  
Jun-20-19 11:48AM  
Jun-07-19 09:27AM  
May-20-19 07:15AM  
May-08-19 05:25PM  
May-01-19 10:32AM  
Apr-30-19 04:05PM  
Apr-20-19 09:27AM  
Apr-15-19 04:30PM  
Apr-12-19 10:08AM  
Apr-04-19 08:30AM  
Apr-01-19 09:05AM  
Mar-28-19 08:00AM  
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haskel William M.Sr. VP, Sec. & General CounselMay 12Sale4.754,66622,164198,690May 14 06:42 PM
Brenner Randall B.Chief Development & RegulatoryMay 12Sale4.756,19829,441130,813May 14 06:38 PM
Woodrow AdamPresident & Chief CommercialMay 12Sale4.754,79822,791270,673May 14 06:30 PM
Loh EvanCEOMay 12Sale4.759,59545,576552,008May 14 06:27 PM
BIGHAM MICHAELExec. Chairman of the BoardMay 12Sale4.6812,25057,330542,167May 14 06:23 PM
Haskel William M.Sr. VP, Sec. & General CounselDec 12Sale3.102,8648,878158,356Dec 16 06:11 PM
Brenner Randall B.Chief Development & RegulatoryDec 12Sale3.106,27819,46292,011Dec 16 06:08 PM
Loh EvanCEODec 12Sale3.1014,51444,993417,603Dec 16 06:06 PM
Woodrow AdamPresident & Chief CommercialDec 12Sale3.104,40113,643207,971Dec 16 06:03 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.